Xponance Inc. Reduces Position in Hologic, Inc. $HOLX

Xponance Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 26.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 36,504 shares of the medical equipment provider’s stock after selling 13,224 shares during the period. Xponance Inc.’s holdings in Hologic were worth $2,464,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Winnow Wealth LLC acquired a new stake in Hologic in the 3rd quarter valued at about $26,000. Root Financial Partners LLC purchased a new position in shares of Hologic during the 3rd quarter worth $27,000. SJS Investment Consulting Inc. boosted its position in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 362 shares during the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the 2nd quarter valued at about $33,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 310 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of HOLX stock opened at $75.45 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The firm has a market cap of $16.84 billion, a P/E ratio of 31.44, a P/E/G ratio of 2.24 and a beta of 0.73. The firm’s 50 day moving average price is $74.96 and its 200-day moving average price is $72.22. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.49.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $0.87 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on HOLX. Morgan Stanley lifted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research report on Friday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Finally, Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Two analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.